Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
9.97
+0.34 (3.53%)
Jun 6, 2025, 4:00 PM - Market closed
Arcus Biosciences Employees
Arcus Biosciences had 627 employees as of December 31, 2024. The number of employees increased by 50 or 8.67% compared to the previous year.
Employees
627
Change (1Y)
50
Growth (1Y)
8.67%
Revenue / Employee
$224,880
Profits / Employee
-$623,604
Market Cap
1.06B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
RCUS News
- 5 days ago - Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response - Business Wire
- 10 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 4 weeks ago - Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update - Business Wire
- 6 weeks ago - Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting - Business Wire
- 6 weeks ago - Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update - Business Wire
- 2 months ago - Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts - Seeking Alpha
- 3 months ago - Arcus Biosciences to Participate in Two Upcoming Investor Conferences - Business Wire